OraSure Technologies, Inc. (NASDAQ:OSUR) Receives $10.00 Average Target Price from Analysts

OraSure Technologies, Inc. (NASDAQ:OSUR) has been assigned an average recommendation of “Sell” from the six analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation and one has assigned a hold recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

OSUR has been the topic of several recent analyst reports. Canaccord Genuity lowered OraSure Technologies from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research report on Thursday, May 9th. BidaskClub lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, July 18th. Finally, Zacks Investment Research lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, July 9th.

Shares of OSUR traded down $0.33 during trading hours on Tuesday, hitting $7.53. The company had a trading volume of 353,660 shares, compared to its average volume of 486,320. The company has a market cap of $487.72 million, a P/E ratio of 15.06, a PEG ratio of 2.52 and a beta of 1.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.99 and a quick ratio of 6.56. OraSure Technologies has a one year low of $7.15 and a one year high of $17.11. The business’s fifty day moving average price is $8.64.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.04. OraSure Technologies had a return on equity of 7.81% and a net margin of 11.83%. The company had revenue of $38.83 million for the quarter, compared to analyst estimates of $41.48 million. During the same period in the prior year, the company posted $0.07 EPS. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. Sell-side analysts predict that OraSure Technologies will post 0.25 earnings per share for the current year.

In other OraSure Technologies news, SVP Jack E. Jerrett bought 10,000 shares of OraSure Technologies stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $8.55 per share, with a total value of $85,500.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Roble Belko & Company Inc acquired a new position in shares of OraSure Technologies in the first quarter valued at about $29,000. Acadian Asset Management LLC acquired a new position in shares of OraSure Technologies in the second quarter valued at about $25,000. Parallel Advisors LLC acquired a new position in shares of OraSure Technologies in the first quarter valued at about $33,000. Quantamental Technologies LLC acquired a new position in shares of OraSure Technologies in the first quarter valued at about $56,000. Finally, Panagora Asset Management Inc. increased its holdings in shares of OraSure Technologies by 34.3% in the second quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 2,514 shares during the period. 91.55% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Day Trading – Risk Worth the Reward?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.